keyword
MENU ▼
Read by QxMD icon Read
search

statin and kidney

keyword
https://www.readbyqxmd.com/read/29792269/pcsk9-inhibition-ready-for-prime-time-in-ckd
#1
Marion Mafham, Richard Haynes
Lowering LDL cholesterol reduces the risk of atherosclerotic vascular disease in a wide range of patients with chronic kidney disease, with no evidence of a threshold below which further reductions no longer reduce risk. Statins safely lower LDL cholesterol, but novel inhibitors of proprotein convertase subtilisin kexin 9 (PCSK9) provide additional reductions which may reduce atherosclerotic vascular disease yet further in this high risk population.
June 2018: Kidney International
https://www.readbyqxmd.com/read/29789011/novel-phenoxazinones-as-potent-agonist-of-ppar-%C3%AE-design-synthesis-molecular-docking-and-in-vivo-studies
#2
David I Ugwu, Uchechukwu C Okoro, Narendra K Mishra, Sunday N Okafor
BACKGROUND: The use of statin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for the treatment of dyslipidemia has been associated with dose limiting hepatoxicity, mytotoxicity and tolerability due to myalgias thereby necessitating the synthesis of new drug candidates for the treatment of lipid disorder. METHODS: The reaction of appropriate benzenesulphonamide with substituted phenoxazinone in the presence of phenylboronic acid gave the targeted compounds...
May 22, 2018: Lipids in Health and Disease
https://www.readbyqxmd.com/read/29784023/delayed-presentation-of-severe-rhabdomyolysis-leading-to-acute-kidney-injury-following-atorvastatin-gemfibrozil-combination-therapy-a-case-report
#3
Chamara Dalugama, Manoji Pathirage, S A M Kularatne
BACKGROUND: Rhabdomyolysis is a rare but serious complication of lipid-lowering therapy. Statin and fibrate combination increases the risk of rhabdomyolysis possibly by pharmacodynamic interactions. Advanced age, diabetes, hypothyroidism, polypharmacy, and renal impairment are known to increase the risk of rhabdomyolysis. Management strategies include fluid resuscitation and urine alkalinization. Renal indications such as refractory hyperkalemia, acidosis, fluid overload, or uremic complications mandate renal replacement therapy in rhabdomyolysis...
May 22, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29778569/mevalonate-pathway-blockage-enhances-the-efficacy-of-mtor-inhibitors-with-the-activation-of-retinoblastoma-protein-in-renal-cell-carcinoma
#4
Nobuhisa Hagiwara, Motoki Watanabe, Mahiro Iizuka-Ohashi, Isao Yokota, Seijiro Toriyama, Mamiko Sukeno, Mitsuhiro Tomosugi, Yoshihiro Sowa, Fumiya Hongo, Kazuya Mikami, Jintetsu Soh, Akira Fujito, Hiroaki Miyashita, Yukako Morioka, Tsuneharu Miki, Osamu Ukimura, Toshiyuki Sakai
Renal cell carcinoma (RCC) is the most common malignancy of kidney and remains largely intractable once it recurs after resection. mTOR inhibitors have been one of the mainstays used against recurrent RCC; however, there has been a major problem of the resistance to mTOR inhibitors, and thus new combination treatments with mTOR inhibitors are required. We here retrospectively showed that regular use of antilipidemic drug statins could provide a longer progression free survival (PFS) in RCC patients prescribed with an mTOR inhibitor everolimus than without statins (median PFS, 7...
May 17, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29770749/rosuvastatin-and-atorvastatin-preserve-renal-function-in-hiv-1-infected-patients-with-chronic-kidney-disease-and-hyperlipidaemia
#5
Leonardo Calza, Vincenzo Colangeli, Marco Borderi, Roberto Manfredi, Lorenzo Marconi, Isabella Bon, Maria Carla Re, Pierluigi Viale
BACKGROUND: Hyperlipidaemia is a risk factor for the progression of chronic kidney disease (CKD), which is a frequent comorbidity in patients with HIV-1 infection, but the renal effects of statins remain unclear. METHODS: We performed an observational, prospective study of HIV-infected patients on suppressive antiretroviral therapy, with CKD and hyperlipidaemia, and starting a lipid-lowering treatment with rosuvastatin, atorvastatin or omega-3 fatty acids. CKD was defined as an estimated glomerular filtration rate (eGFR) ≤ 60 mL/min/1...
June 2018: HIV Clinical Trials
https://www.readbyqxmd.com/read/29770231/cardiovascular-outcomes-of-pcsk9-inhibitors-with-special-emphasis-on-its-effect-beyond-ldl-cholesterol-lowering
#6
REVIEW
Dhrubajyoti Bandyopadhyay, Kumar Ashish, Adrija Hajra, Arshna Qureshi, Raktim K Ghosh
PCSK9 inhibitors, monoclonal antibodies, are novel antihypercholesterolemic drugs. FDA first approved them in July 2015. PCSK9 protein (692-amino acids) was discovered in 2003. It plays a major role in LDL receptor degradation and is a prominent modulator in low-density lipoprotein cholesterol (LDL-C) metabolism. PCSK9 inhibitors are monoclonal antibodies that target PCSK9 protein in liver and inhibiting this protein leads to drastically lowering harmful LDL-C level in the bloodstream. Despite widespread use of the statin, not all the high-risk patients were able to achieve targeted level of LDL-C...
2018: Journal of Lipids
https://www.readbyqxmd.com/read/29760658/high-plasma-exposure-of-statins-associated-with-increased-risk-of-contrast-induced-acute-kidney-injury-in-chinese-patients-with-coronary-artery-disease
#7
Liyun Cai, Xue Bai, Heping Lei, Hong Wu, Yong Liu, Qian Zhu, Shanshan Zhang, Yibin Liu, Qiuxiong Lin, Jiyan Chen, Bin Zhang, Guodong He, Qingshan Geng, Min Huang, Shilong Zhong
The role of statins in reducing the incidence of contrast-induced acute kidney injury (CI-AKI) remains controversial. We sought to evaluate the association between CI-AKI and high plasma exposure of statins in coronary artery disease (CAD) patients undergoing coronary angiography (CAG). This association was first evaluated in 1,219 patients with CAD receiving atorvastatin (AT) therapy and validated in 635 patients receiving rosuvastatin (RST) therapy. The plasma concentrations of statins were quantified using validated UPLC-MS/MS methods and CI-AKI incidence was assessed during the first 48 h postoperatively...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29748329/oral-antibiotic-exposure-and-kidney-stone-disease
#8
Gregory E Tasian, Thomas Jemielita, David S Goldfarb, Lawrence Copelovitch, Jeffrey S Gerber, Qufei Wu, Michelle R Denburg
Background Although intestinal and urinary microbiome perturbations are associated with nephrolithiasis, whether antibiotics are a risk factor for this condition remains unknown. Methods We determined the association between 12 classes of oral antibiotics and nephrolithiasis in a population-based, case-control study nested within 641 general practices providing electronic health record data for >13 million children and adults from 1994 to 2015 in the United Kingdom. We used incidence density sampling to match 25,981 patients with nephrolithiasis to 259,797 controls by age, sex, and practice at date of diagnosis (index date)...
May 10, 2018: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/29707830/esrd-induced-dyslipidemia-should-management-of-lipid-disorders-differ-in-dialysis-patients
#9
Hamid Moradi, Elani Streja, Nosratola D Vaziri
Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. Although numerous modifiable risk factors in the pathogenesis of CVD and its associated mortality have been identified, dyslipidemia remains to be a key focus for therapy. In this regard, significant progress has been made in reducing cardiovascular mortality via the use of lipid-lowering agents such as HMG CoA reductase inhibitors (statins). Yet, despite the disproportionate risk of CVD and mortality in patients with advanced chronic and end stage renal disease (ESRD), treatment of dyslipidemia in this patient population has not been associated with a notable improvement in outcomes...
April 29, 2018: Seminars in Dialysis
https://www.readbyqxmd.com/read/29701801/determinants-of-uncontrolled-hypertension-in-rural-communities-in-south-asia-bangladesh-pakistan-and-sri-lanka
#10
Tazeen H Jafar, Mihir Gandhi, Imtiaz Jehan, Aliya Naheed, H Asita de Silva, Hunaina Shahab, Dewan Alam, Nathasha Luke, Ching Wee Lim
Background: Uncontrolled blood pressure (BP) is a leading risk factor for death and disability in South Asia. We aimed to determine the cross-country variation, and the factors associated with uncontrolled BP among adults treated for hypertension in rural South Asia. Methods: We enrolled 1718 individuals aged ≥40 years treated for hypertension in a cross-sectional study from rural communities in Bangladesh, Pakistan, and Sri Lanka. Multivariable logistic regression model was used to determine the factors associated with uncontrolled BP (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg)...
April 26, 2018: American Journal of Hypertension
https://www.readbyqxmd.com/read/29696241/blood-pressure-and-metabolic-effects-of-acetyl-l-carnitine-in-type-2-diabetes-diabasi-randomized-controlled-trial
#11
Aneliya Parvanova, Matias Trillini, Manuel A Podestà, Ilian P Iliev, Carolina Aparicio, Annalisa Perna, Francesco Peraro, Nadia Rubis, Flavio Gaspari, Antonio Cannata, Silvia Ferrari, Antonio C Bossi, Roberto Trevisan, Sreejith Parameswaran, Jonathan S Chávez-Iñiguez, Fahrudin Masnic, Sidy Mohamed Seck, Teerayuth Jiamjariyaporn, Monica Cortinovis, Luca Perico, Kanishka Sharma, Giuseppe Remuzzi, Piero Ruggenenti, David G Warnock
Context: Acetyl-l-carnitine (ALC), a mitochondrial carrier involved in lipid oxidation and glucose metabolism, decreased systolic blood pressure (SBP), and ameliorated insulin sensitivity in hypertensive nondiabetic subjects at high cardiovascular risk. Objective: To assess the effects of ALC on SBP and glycemic and lipid control in patients with hypertension, type 2 diabetes mellitus (T2D), and dyslipidemia on background statin therapy. Design: After 4-week run-in period and stratification according to previous statin therapy, patients were randomized to 6-month, double-blind treatment with ALC or placebo added-on simvastatin...
May 1, 2018: Journal of the Endocrine Society
https://www.readbyqxmd.com/read/29679711/establishment-of-a-drug-induced-rhabdomyolysis-mouse-model-by-co-administration-of-ciprofloxacin-and-atorvastatin
#12
Akiko Matsubara, Shingo Oda, Sho Akai, Koichi Tsuneyama, Tsuyoshi Yokoi
Rhabdomyolysis is one of the serious side effects of ciprofloxacin (CPFX), a widely used antibacterial drug; and occasionally, acute kidney injury (AKI) occurs. Often, rhabdomyolysis has occurred in patients taking CPFX co-administered with statins. The purpose of this study is to establish a mouse model of drug-induced rhabdomyolysis by co-administration of CPFX and atorvastatin (ATV) and to clarify the mechanisms of its pathogenesis. C57BL/6J mice treated with L-buthionine-(S,R)-sulfoximine (BSO), a glutathione synthesis inhibitor, were orally administered with CPFX and ATV for 4 days...
April 18, 2018: Toxicology Letters
https://www.readbyqxmd.com/read/29669332/paritaprevir-ritonavir-ombitasvir-plus-dasabuvir-regimen-in-the-treatment-of-genotype-1-chronic-hepatitis-c-infection-in-patients-with-severe-renal-impairment-and-end-stage-renal-disease-a-real-life-cohort
#13
Jan Sperl, Miluse Kreidlova, Dusan Merta, Klara Chmelova, Renata Senkerikova, Sona Frankova
BACKGROUND/AIMS: Chronic hepatitis C (HCV) virus infection reactivates under immunosuppressive drugs and therefore has a negative impact on long-term survival of kidney transplant recipients. Treatment-induced clearance of hepatitis C virus (HCV) in kidney transplant candidates prevents virus reactivation after transplantation. Paritaprevir/Ritonavir/Ombitasvir with Dasabuvir (PrOD) represents a highly effective treatment regimen for HCV genotype 1 (GT1), also suitable for patients with end-stage renal disease (ESRD)...
April 13, 2018: Kidney & Blood Pressure Research
https://www.readbyqxmd.com/read/29665812/effects-of-statin-therapy-on-chronic-kidney-disease-patients-with-coronary-artery-disease
#14
Hao Shen, Xiaodong Chen, Jingfen Lu, Honglin Yang, Yan Xu, Ao Zhu, Xiao Zhang, Fulong Ye, Yongchun Gu
BACKGROUND: Long-term persistence of statin therapy provided an ongoing reduction in mortality among patients with and without a known history of CVD, and renoprotective effect on CKD patients. Until now, very few reports are available from China to address the effects of statin therapy in CKD + CAD patients. METHODS: We compared the effects of long-term statin therapy (follow-up time 4 years) in terms of cardiovascular events, all-cause death, and cardiac death among 254 CKD patients with or without CAD...
April 17, 2018: Lipids in Health and Disease
https://www.readbyqxmd.com/read/29627112/impact-of-chronic-kidney-disease-on-outcomes-after-percutaneous-coronary-intervention-for-chronic-total-occlusions-from-the-japanese-multicenter-registry
#15
Toru Naganuma, Kenichi Tsujita, Satoru Mitomo, Hisaaki Ishiguro, Sandeep Basavarajaiah, Katsumasa Sato, Tsuyoshi Kobayashi, Junei Obata, Suguru Nagamatsu, Kenshi Yamanaga, Naohiro Komura, Kenji Sakamoto, Eiichiro Yamamoto, Yasuhiro Izumiya, Sunao Kojima, Koichi Kaikita, Hisao Ogawa, Sunao Nakamura
The impact of chronic kidney disease (CKD) and potential pharmacologic intervention on clinical outcomes after percutaneous coronary intervention (PCI) for chronic total occlusions (CTOs) remains unknown. A total of 1,463 patients underwent successful CTO-PCI between August 2004 and December 2014. Major adverse cardiovascular events (MACE) defined as the composite of all-cause death, myocardial infarction and target lesion revascularization, cardiac death, and stent thrombosis were compared between patients with and without CKD (555 and 908 patients, respectively)...
March 13, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29617505/evaluation-of-the-effects-of-atorvastatin-and-ischemic-postconditioning-preventing-on-the-ischemia-and-reperfusion-injury-experimental-study-in-rats
#16
Henrique Budib Dorsa Pontes, José Carlos Dorsa Vieira Pontes, Euler de Azevedo Neto, Giovanna Serra da Cruz Vendas, João Victor Cunha Miranda, Letícia do Espírito Santos Dias, João Victor Durães Gomes Oliva, Murilo Henrique Martins de Almeida, Ian de Oliveira Chaves, Tricia Luna Sampaio, Carlos Henrique Marques Dos Santos, Doroty Mesquita Dourado
INTRODUCTION: Reperfusion injury leads to systemic morphological and functional pathological alterations. Some techniques are already estabilished to attenuate the damage induced by reperfusion. Ischemic preconditioning is one of the standard procedures. In the last 20 years, several experimental trials demonstrated that the ischemic postconditioning presents similar effectiveness. Recently experimental trials demonstrated that statins could be used as pharmacological preconditioning...
January 2018: Brazilian Journal of Cardiovascular Surgery
https://www.readbyqxmd.com/read/29617000/statins-and-new-onset-diabetes-in-cardiovascular-and-kidney-disease-cohorts-a-meta-analysis
#17
Haroon Kamran, Eric Kupferstein, Navneet Sharma, Jocelyne G Karam, Alyson K Myers, Irini Youssef, James R Sowers, Deborah R Gustafson, Moro O Salifu, Samy I McFarlane
BACKGROUND: Statins have long been prescribed for the primary and secondary prevention of cardiovascular disease (CVD) and kidney disease. Their benefits and efficacy are widely accepted in current clinical practice, but like any other therapeutic agents, they have adverse effects. One of the emerging concerns with statin therapy is the development of new-onset diabetes mellitus (NODM), a dreaded risk factor for CVD and kidney disease and widely viewed as CVD equivalent. Accumulating evidence indicates that NODM is a consequence of statin use...
2018: Cardiorenal Medicine
https://www.readbyqxmd.com/read/29616526/effects-of-chronic-statin-use-on-30-day-major-adverse-cardiac-and-cerebrovascular-events-after-thoracic-endovascular-aortic-repair
#18
Sung Y Ham, Suk W Song, Sang B Nam, Soo J Park, Sijin Kim, Young Song
BACKGROUND: Cardiac and cerebrovascular complications are major causes of adverse outcomes following thoracic endovascular aortic repair (TEVAR). The benefits of statins have been established, but little is known about their impact on patients undergoing TEVAR. We investigated whether chronic statin use protected against early postoperative major adverse cardiac and cerebrovascular events (MACCEs) after TEVAR. METHODS: We retrospectively reviewed 211 patients who underwent TEVAR between February 2013 and March 2017 classified into two groups, those with acute aortic syndrome (AAS, n=79) and those without (non-AAS, n=132)...
April 3, 2018: Journal of Cardiovascular Surgery
https://www.readbyqxmd.com/read/29611220/cardiovascular-disease-after-transplantation-an-emerging-role-of-the-immune-system
#19
REVIEW
S Van Laecke, T Malfait, E Schepers, W Van Biesen
Cardiovascular disease after transplantation: an emerging role of the immune system. Cardiovascular disease after transplantation remains a major concern. Little is known about what drives the increased cardiovascular risk in transplant recipients apart from traditional risk factors. The immune system is involved in the pathogenesis of hypertension, atherosclerosis, and coronary artery disease in the general population. Recently, inhibition of interleukin 1-β by canakinumab versus placebo decreased the incidence of cardiovascular events...
April 2, 2018: Transplant International: Official Journal of the European Society for Organ Transplantation
https://www.readbyqxmd.com/read/29607300/do-statins-induce-or-protect-from-acute-kidney-injury-and-chronic-kidney-disease-an-update-review-in-2018
#20
An Verdoodt, Patrick M Honore, Rita Jacobs, Elisabeth De Waele, Viola Van Gorp, Jouke De Regt, Herbert D Spapen
Statins essentially are cholesterol-lowering drugs that are extensively prescribed for primary and secondary prevention of cardiovascular disease. Compelling evidence suggests that the beneficial effects of statins may not only be due to its ability to control cholesterol levels but also due to a pleiotropic cholesterol-independent anti-inflammatory, antioxidant, endothelial-protective and plaque-stabilizing activity. Along this line, statins may also exert acute and long-term effects on renal function. We present a narrative literature review that summarizes arguments in favor of or against the preventive and/or therapeutic use of statins in kidney-related diseases or complications...
March 2018: Journal of Translational Internal Medicine
keyword
keyword
45847
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"